News
Most Read

Terns concludes patient enrolment in NASH treatment trial
Celltrion’s Covid-19 drug shows therapeutic efficacy in Phase II trials
GSK and Vir Biotechnology to initiate NHS-backed Covid-19 trial

Most Recent

Clinical Trials

Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC

15 Jan 2021
Analysis
Sections

Features
Comment
Projects
Most Read

Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

Most Recent

Clinical Trials

Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

12 Jan 2021
Sectors
Sections

Clinical Trials
Approvals
Clinical Research
Operations
Outsourcing
Supply Chain
Cold Chain
Data Management
Medical Devices
Most Read

COVID-19 pandemic increasing interest in virtual or decentralised clinical trials, says GlobalData
International update: Global Covid deaths near 2 million as cases pass 93 million
GlobalData Epidemiologist Report: Global Covid cases exceed 92 million – UK death count nears 85,000 – worst in Europe

Most Recent

Clinical Trials

Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC

15 Jan 2021
Themes
Deals
Most Read

Investment firm GI Partners closes Clinical Ink acquisition
Investment firm GI Partners to acquire minority interest in Clinical Ink
IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

Most Recent

Clinical Trials

Investment firm GI Partners closes Clinical Ink acquisition

27 Aug 2020
Companies
Sections

Company A-Z
Company Categories
Products & Services
Company Releases
White Papers
Videos
Most Read

OpenClinica
Strategikon Pharma
IVR Clinical Concepts

Most Recent

Clinical Trials

OpenClinica

30 Dec 2020
Magazine
Events

Menu

News
Analysis
Investment
Sectors
Deals
Tech
Disruption
Coronavirus

Partners

Accelerating Clinical Trials
Simplifying Clinical Trials

Tools

Companies
Awards
Events
Magazine

The Company

About Us
Contact Us
Advertise With Us
Visit GlobalData

Login
Register

Login
Register

ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer

ORGOVYX is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist.

Powered by

About Us
Editorial Approach
Contact Us
Terms and Conditions
Privacy Policy

© Copyright 2021 Verdict Media Limited.

Lost Password Back ⟶
Login
Register

Lost Password?

Registration is disabled.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Continue Learn more